BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55

Bristol-Myers Squibb Company (BMY) has an average rating of hold and price targets ranging from $37 to $75, according to analysts polled by Capital IQ. Price: 44.93, Change: +0.23, Percent Change: +0.

MT Newswires7minutes ago

Jefferies Adjusts Merck & Company Price Target to $150 From $145

Merck & Company (MRK) has an average rating of outperform and price targets ranging from $114 to $155, according to analysts polled by Capital IQ. Price: 131.18, Change: +0.46, Percent Change: +0.35

MT Newswires18minutes ago

Bristol Myers Says EMA's CHMP Recommended Approval Of Opdivo Combination With Cisplatin, Gemcitabine For First-line Treatment Of Adult Patients With Unresectable Or Metastatic Urothelial Carcinoma

The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation. The final EC decision is expected in June 2024.

Benzinga21minutes ago

UPDATE 1-US FDA Approves Pfizer's Gene Therapy for Rare Bleeding Disorder

Yahoo Finance25minutes ago

Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B

By Colin Kellaher Pfizer has won Food and Drug Administration approval of Beqvez, a one-time gene therapy for certain patients with the inherited bleeding disorder hemophilia B. The New York drugmak

WSJ26minutes ago

Pfizer Says U.S. FDA Approved Company's BEQVEZ (Fidanacogene Elaparvovec-dzkt), A One-Time Gene Therapy For Adults With Hemophilia B; Company Now Plans Launching An Innovative Warranty Program Based On Durability Of Patient Response To Treatment

With BEQVEZ now approved for use, Pfizer is launching an innovative warranty program based on durability of patient response to treatment. The goal of the warranty is to provide greater certainty to p

Benzinga37minutes ago